Bridge Biotherapeutics Inc
Parataxis Korea, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide. Its products in pipeline includes BBT-401, a Pellino-1 inhibitor, which is in Phase I clinical trial for the treatment of ulcerative colitis; and BBT-877, an autotaxin inhibitor that is in Phase I clinical trial for … Read more
Bridge Biotherapeutics Inc (288330) - Total Assets
Latest total assets as of September 2025: ₩55.57 Billion KRW
Based on the latest financial reports, Bridge Biotherapeutics Inc (288330) holds total assets worth ₩55.57 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Bridge Biotherapeutics Inc - Total Assets Trend (2016–2024)
This chart illustrates how Bridge Biotherapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Bridge Biotherapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Bridge Biotherapeutics Inc's total assets of ₩55.57 Billion consist of 69.8% current assets and 30.3% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩5.74 Billion | 17.1% |
| Accounts Receivable | ₩203.40 Million | 0.6% |
| Inventory | ₩0.00 | 0.0% |
| Property, Plant & Equipment | ₩3.04 Billion | 9.1% |
| Intangible Assets | ₩2.96 Billion | 8.8% |
| Goodwill | ₩2.37 Billion | 7.1% |
Asset Composition Trend (2016–2024)
This chart illustrates how Bridge Biotherapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bridge Biotherapeutics Inc's current assets represent 69.8% of total assets in 2024, a decrease from 98.2% in 2016.
- Cash Position: Cash and equivalents constituted 17.1% of total assets in 2024, up from 1.0% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 15.0% of total assets, an increase from 1.0% in 2016.
- Asset Diversification: The largest asset category is cash and equivalents at 17.1% of total assets.
Bridge Biotherapeutics Inc Competitors by Total Assets
Key competitors of Bridge Biotherapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MGT Capital Investments Inc
PINK:MGTI
|
USA | $36.00K |
|
XTRA Bitcoin Inc
PINK:CBTC
|
USA | $109.64K |
|
Shenwan Hongyuan Group Co Ltd
SHE:000166
|
China | CN¥721.97 Billion |
|
Northeast Securities Co Ltd
SHE:000686
|
China | CN¥110.06 Billion |
|
Guangdong Golden Dragon Development Inc
SHE:000712
|
China | CN¥22.93 Billion |
|
Sealand Securities Co Ltd
SHE:000750
|
China | CN¥74.96 Billion |
|
GF Securities Co Ltd
SHE:000776
|
China | CN¥953.44 Billion |
|
Changjiang Securities Co Ltd
SHE:000783
|
China | CN¥191.54 Billion |
Bridge Biotherapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Bridge Biotherapeutics Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Bridge Biotherapeutics Inc is currently not profitable relative to its asset base.
Bridge Biotherapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.81 | 4.56 | 57.14 |
| Quick Ratio | 8.81 | 4.56 | 57.14 |
| Cash Ratio | 0.00 | 2.86 | 0.00 |
| Working Capital | ₩21.57 Billion | ₩ 21.07 Billion | ₩ 59.25 Billion |
Bridge Biotherapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Bridge Biotherapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.38 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -2.1% |
| Total Assets | ₩33.49 Billion |
| Market Capitalization | $22.91 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bridge Biotherapeutics Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Bridge Biotherapeutics Inc's assets decreased by 2.1% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Bridge Biotherapeutics Inc (2016–2024)
The table below shows the annual total assets of Bridge Biotherapeutics Inc from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩33.49 Billion | -2.13% |
| 2023-12-31 | ₩34.22 Billion | -44.31% |
| 2022-12-31 | ₩61.46 Billion | +31.72% |
| 2021-12-31 | ₩46.66 Billion | -26.54% |
| 2020-12-31 | ₩63.51 Billion | -20.35% |
| 2019-12-31 | ₩79.74 Billion | +585.02% |
| 2018-12-31 | ₩11.64 Billion | -38.77% |
| 2017-12-31 | ₩19.01 Billion | +45.04% |
| 2016-12-31 | ₩13.11 Billion | -- |